Adela Fernández-Ortega

The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis

Marta Vaz Batista, José Manuel Pérez-García, Laia Garrigós et al. · Med · 2024 · 33 citations

Breast Oncology, Medicine, Leptomeningeal Carcinomatosis +6

Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial

Marta Vaz Batista, José Manuel Pérez-García, Patricia Cortez et al. · ESMO Open · 2024 · 26 citations · Full text

Breast Oncology, Oncology, Breast Cancer +5

PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution

Sònia Pernas, Anna Petit, Fina Climent et al. · Frontiers in Oncology · 2019 · 25 citations · Full text

Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial

Antonio Llombart‐Cussac, José Manuel Pérez-García, Manuel Ruíz Borrego et al. · EClinicalMedicine · 2024 · 19 citations · Full text

Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center

Milana A. Bergamino, Adela Fernández-Ortega, Agostina Stradella et al. · BMC Pharmacology and Toxicology · 2019 · 14 citations · Full text